Tolerability-Adapted Imatinib 800 mg/d Versus 400 mg/d Versus 400 mg/d Plus Interferon-α in Newly Diagnosed Chronic Myeloid Leukemia
Rüdiger Hehlmann(Heidelberg University), Susanne Saußele(University of Mannheim), Brigitte Schlegelberger(Heidelberg University), Andreas Hochhaus(Jena University Hospital), Nadine Pletsch(Universität Hamburg), Leopold Balleisen(Evangelisches Krankenhaus Hamm), Susanne Jung-Munkwitz(Universität Hamburg), Mathias Hänel(Klinikum Chemnitz), Markus Pfirrmann(Ludwig-Maximilians-Universität München), Michael Lauseker(Zimmer Biomet (Germany)), Armin Leitner(Universität Hamburg), Aloïs Gratwohl, Stefan W. Krause(Universitätsklinikum Erlangen), Joerg Hasford(Ludwig-Maximilians-Universität München), Ulrike Proetel(Heidelberg University), Martin C. Müller(Universität Hamburg), Dieter K. Hossfeld(Universität Hamburg), Christoph Nerl(Universität Hamburg), H. Pralle(University of Mannheim), Claudia Haferlach(Munich Leukemia Laboratory (Germany))
Cited by 323
Related Papers
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
|Leukemia|2022|3.8k
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)
|The Lancet Oncology|2008|1.1k
Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial
|Leukemia|2016|849
A New Prognostic Score for Survival of Patients With Chronic Myeloid Leukemia Treated With Interferon Alfa Writing Committee for the Collaborative CML Prognostic Factors Project Group
|JNCI Journal of the National Cancer Institute|1998|820